Talis Biomedical Co. (NASDAQ:TLIS – Get Rating) was down 1% on Friday . The company traded as low as $0.59 and last traded at $0.60. Approximately 109,802 shares were traded during mid-day trading, a decline of 12% from the average daily volume of 124,413 shares. The stock had previously closed at $0.61.
Talis Biomedical Stock Performance
The company has a 50-day moving average of $0.54 and a 200-day moving average of $0.67.
Get
Talis Biomedical alerts:
Talis Biomedical (NASDAQ:TLIS – Get Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.24). Talis Biomedical had a negative return on equity of 59.90% and a negative net margin of 2,119.66%. The business had revenue of $0.80 million during the quarter, compared to the consensus estimate of $0.20 million. Research analysts predict that Talis Biomedical Co. will post -4.03 earnings per share for the current year.
Hedge Funds Weigh In On Talis Biomedical
A number of large investors have recently bought and sold shares of the business. Prelude Capital Management LLC raised its position in shares of Talis Biomedical by 36.2% during the 1st quarter. Prelude Capital Management LLC now owns 256,395 shares of the company's stock worth $362,000 after purchasing an additional 68,126 shares during the period. Millennium Management LLC bought a new position in Talis Biomedical during the 2nd quarter worth $164,000. Finally, Renaissance Technologies LLC increased its position in Talis Biomedical by 549.3% in the second quarter. Renaissance Technologies LLC now owns 107,765 shares of the company's stock worth $88,000 after buying an additional 91,167 shares during the period. Institutional investors own 47.08% of the company's stock.
Talis Biomedical Company Profile
(Get Rating)
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19.
Featured Stories
- Get a free copy of the StockNews.com research report on Talis Biomedical (TLIS)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
Receive News & Ratings for Talis Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talis Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
塔利斯生物醫療公司(TLIS-GET Rating)上週五下跌1%。該公司股價低至0.59美元,最新報0.60美元。午盤成交量約為109,802股,較124,413股的日均成交量下降12%。該股此前收盤價為0.61美元。
Talis Biomedical股票表現
該公司的50日移動均線切入位在0.54美元,200日移動均線切入位在0.67美元。
到達
塔利斯生物醫學警報:
塔利斯生物醫療(納斯達克:TLIS-GET Rating)最近一次公佈季度收益是在11月3日星期四。該公司公佈本季度每股收益(EPS)為0.98美元,低於分析師一致預期的0.74美元和0.24美元。Talis Biomedical的淨資產回報率為負59.90%,淨利潤率為負2119.66%。該業務本季度的收入為80萬美元,而普遍預期為20萬美元。研究分析師預計,Talis Biomedical Co.本年度每股收益將達到4.03美元。
對沖基金入股Talis Biomedical
一些大型投資者最近買賣了該公司的股票。Prelude Capital Management LLC在第一季度將其在Talis Biomedical股票中的頭寸提高了36.2%。Prelude Capital Management LLC現在擁有256,395股該公司的股票,價值362,000美元,在此期間又購買了68,126股。Millennium Management LLC在第二季度購買了Talis Biomedical的一個新頭寸,價值16.4萬美元。最後,復興科技有限責任公司在第二季度將其在Talis Biomedical的頭寸增加了549.3%。復興科技有限責任公司現在擁有107,765股該公司的股票,價值88,000美元,在此期間又購買了91,167股。機構投資者持有該公司47.08%的股份。
Talis Biomedical公司簡介
(獲取評級)
Talis Biomedical Corporation是一家分子診斷公司。該公司正在開發Talis One系統,以解決現有傳染病護理點診斷檢測技術的侷限性。它還為Talis One新冠肺炎提供檢測系統,該系統專注於檢測導致新冠肺炎的SARS-CoV-2病毒。
專題報道
- 免費獲取StockNews.com關於Talis Biomedical(TLIS)的研究報告
- 市場回顧周-1/30-2/3
- 細價股值得嗎?你應該投資細價股嗎?
- Zimmer Biomet盈利節節攀升,增長可能被計入價格
- 人工智慧軟體製造商EPAM號稱科技板塊漲幅最大
- 福特股票在盈利大幅下滑後繼續前進
接受《塔利斯生物醫學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Talis Biomedical和相關公司的最新新聞和分析師評級的每日簡要摘要。